

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

SCHEDULE 13G  
(Rule 13d-102)

Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c)  
and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2

Under the Securities Exchange Act of 1934  
(Amendment No. )

**TransMedics Group, Inc.**

---

(Name of Issuer)

---

**Common Stock, \$.0001 par value**

(Title of Class of Securities)

---

**89377M 109**

(CUSIP Number)

---

**May 1, 2019**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

---

1. Names of Reporting Persons  
I.R.S. Identification Nos. of Above Persons (entities only)  
United Therapeutics Corporation  
52-1984749

---

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

---

3. SEC Use Only

---

4. Citizenship or Place of Organization  
Delaware

---

5. Sole Voting Power  
0

---

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

6. Shared Voting Power  
1,458,413

---

7. Sole Dispositive Power  
0

---

8. Shared Dispositive Power  
1,458,413

---

9. Aggregate Amount Beneficially Owned by Each Reporting Person  
1,458,413

---

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

---

11. Percent of Class Represented by Amount in Row (9)  
6.89%

---

12. Type of Reporting Person (See Instructions)  
CO

---

1. Names of Reporting Persons  
I.R.S. Identification Nos. of Above Persons (entities only)  
Lung Biotechnology PBC  
52-2225205

---

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

---

3. SEC Use Only

---

4. Citizenship or Place of Organization  
Delaware

---

5. Sole Voting Power  
0

---

Number of  
Shares  
Beneficially  
Owned by  
Each  
Reporting  
Person With

6. Shared Voting Power  
1,458,413

---

7. Sole Dispositive Power  
0

---

8. Shared Dispositive Power  
1,458,413

---

9. Aggregate Amount Beneficially Owned by Each Reporting Person  
1,458,413

---

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

---

11. Percent of Class Represented by Amount in Row (9)  
6.89%

---

12. Type of Reporting Person (See Instructions)  
CO

---

**Item 1.**

- (a) **Name of Issuer:**  
TransMedics Group, Inc.
- 
- (b) **Address of Issuer's Principal Executive Offices:**  
200 Minuteman Road, Andover, MA 01810
- 

**Item 2.**

- (a) **Name of Persons Filing:**  
United Therapeutics Corporation  
Lung Biotechnology PBC
- 
- (b) **Address of Principal Business Office or, if none, Residence:**  
1040 Spring Street  
Siler Spring, MD 20910
- 
- (c) **Citizenship:**  
United Therapeutics Corporation is a Delaware corporation and Lung Biotechnology is a Delaware public benefit corporation
- 
- (d) **Title of Class of Securities:**  
Common Stock
- 
- (e) **CUSIP Number:**  
89377M 109
- 

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:**

Not applicable

- (a)  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d)  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
- (k)  Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership.**

(a) Amount beneficially owned:  
1,458,413

---

(b) Percent of class: 6.89%

---

(c) Number of shares as to which the person has:

---

(i) Sole power to vote or to direct the vote  
0

---

(ii) Shared power to vote or to direct the vote  
1,458,413

---

(iii) Sole power to dispose or to direct the disposition of  
0

---

(iv) Shared power to dispose or to direct the disposition of  
1,458,413

---

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following .

Not applicable

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**

Lung Biotechnology PBC is a wholly-owned subsidiary of United Therapeutics Corporation.

**Item 8. Identification and Classification of Members of the Group.**

Please see Item 3.

**Item 9. Notice of Dissolution of Group.**

Not applicable.

**Item 10. Certifications.**

Not applicable.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 7, 2020

UNITED THERAPEUTICS CORPORATION

By: /s/ John S. Hess, Jr.

Name: John S. Hess, Jr.

Title: Executive Vice President, Deputy General Counsel and Assistant Secretary

Date: February 7, 2020

LUNG BIOTECHNOLOGY PBC

By: /s/ John S. Hess, Jr.

Name: John S. Hess, Jr.

Title: Executive Vice President, Deputy General Counsel and Assistant Secretary

---